Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy
Introduction: Despite the recognized importance of atrophy in multiple sclerosis (MS), methods for its quantification have been mostly restricted to the research domain. Recently, a CE labelled and FDA approved MS-specific atrophy quantification method, MSmetrix, has become commercially available. H...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-01-01
|
Series: | NeuroImage: Clinical |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213158217301651 |